Spruce Biosciences amends CEO Szwarcberg's equity vesting acceleration terms

SPRUCE BIOSCIENCES, INC.

Amendment to CEO Javier Szwarcberg's offer letter dated April 6, 2022.
Vesting acceleration under Severance Plan for Second Stock Option now only applies to Change in Control with effective date on or after January 3, 2023.
All other terms and conditions of the offer letter remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.